📊 IMA Key Takeaways
Is ImageneBio, Inc. (IMA) a Good Investment?
ImageneBio exhibits fundamental business failure indicators: essentially zero revenue (800K), massive operating losses (-5668.6% net margin), and severely negative free cash flow (-48.3M annually). While the balance sheet provides approximately 2 years of cash runway, the complete absence of revenue generation and unsustainable burn rate indicate the company has not achieved commercial viability or demonstrated a clear path to profitability.
ImageneBio has negligible revenue and extremely negative margins alongside heavy operating and free cash flow burn, indicating a pre-commercial profile with weak near-term fundamentals. A strong balance sheet with substantial cash and no debt provides roughly two years of runway, but without evidence of revenue traction or improving unit economics, downside fundamental risk remains elevated.
Why Buy ImageneBio, Inc. Stock? IMA Key Strengths
- Strong balance sheet with 94.5M in cash reserves and zero debt (0.00x debt/equity ratio)
- Excellent liquidity position (12.49x current ratio) provides operational runway for continued development
- Net loss improvement trend with 13.4% YoY reduction in losses, indicating some operational progress
- Robust liquidity ($94.5M cash) and 12.5x current ratio
- No debt; low liabilities vs. assets
- Low capex needs; sizable equity cushion
IMA Stock Risks: ImageneBio, Inc. Investment Risks
- Unsustainable cash burn rate of 47.8M annually with only ~2 year runway remaining at current burn
- Essentially pre-revenue business (800K revenue) with no meaningful commercial traction
- Massive operating losses (-5668.6% net margin) with no visible path to profitability in current financial data
- Negative operating cash flow (-47.8M) demonstrates the business model is not self-sustaining
- Zero year-over-year revenue growth indicates stagnation in core business activity
- Sustained operating losses and ~-$48M annual cash burn
- Minimal revenue (flat YoY) and no gross margin visibility
- Dilution risk to fund R&D/commercialization despite runway
Key Metrics to Watch
- Quarterly cash burn rate trend and remaining cash runway sustainability
- Revenue growth acceleration and path to positive operating cash flow
- Operating cash flow improvement trajectory and timeline to breakeven
- Operating cash flow burn rate and cash runway
- Revenue growth and operating margin trend
ImageneBio, Inc. (IMA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 12.49x current ratio provides a solid financial cushion.
IMA Profit Margin, ROE & Profitability Analysis
IMA vs Healthcare Sector: How ImageneBio, Inc. Compares
How ImageneBio, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ImageneBio, Inc. Stock Overvalued? IMA Valuation Analysis 2026
Based on fundamental analysis, ImageneBio, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ImageneBio, Inc. Balance Sheet: IMA Debt, Cash & Liquidity
IMA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: ImageneBio, Inc.'s revenue has declined by 89% over the 5-year period, indicating business contraction. The most recent EPS of $-22.10 indicates the company is currently unprofitable.
IMA Revenue Growth, EPS Growth & YoY Performance
IMA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $800.0K | -$3.2M | $-2.58 |
| Q3 2024 | $1.2M | -$10.2M | $-0.21 |
| Q2 2024 | $2.0M | -$13.7M | $-0.28 |
| Q1 2024 | $5.3M | -$14.2M | $-0.33 |
| Q3 2023 | $1.2M | -$14.2M | $-0.40 |
| Q2 2023 | $382.0K | -$14.2M | $-0.44 |
| Q1 2023 | $3.4M | -$14.2M | $-0.39 |
| Q3 2022 | $3.7M | -$9.7M | $-0.40 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ImageneBio, Inc. Dividends, Buybacks & Capital Allocation
IMA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for ImageneBio, Inc. (CIK: 0001835579)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IMA
What is the AI rating for IMA?
ImageneBio, Inc. (IMA) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IMA's key strengths?
Claude: Strong balance sheet with 94.5M in cash reserves and zero debt (0.00x debt/equity ratio). Excellent liquidity position (12.49x current ratio) provides operational runway for continued development. ChatGPT: Robust liquidity ($94.5M cash) and 12.5x current ratio. No debt; low liabilities vs. assets.
What are the risks of investing in IMA?
Claude: Unsustainable cash burn rate of 47.8M annually with only ~2 year runway remaining at current burn. Essentially pre-revenue business (800K revenue) with no meaningful commercial traction. ChatGPT: Sustained operating losses and ~-$48M annual cash burn. Minimal revenue (flat YoY) and no gross margin visibility.
What is IMA's revenue and growth?
ImageneBio, Inc. reported revenue of $800.0K.
Does IMA pay dividends?
ImageneBio, Inc. does not currently pay dividends.
Where can I find IMA SEC filings?
Official SEC filings for ImageneBio, Inc. (CIK: 0001835579) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IMA's EPS?
ImageneBio, Inc. has a diluted EPS of $-9.64.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IMA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, ImageneBio, Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IMA stock overvalued or undervalued?
Valuation metrics for IMA: ROE of -34.1% (sector avg: 15%), net margin of -5,668.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IMA stock in 2026?
Our dual AI analysis gives ImageneBio, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IMA's free cash flow?
ImageneBio, Inc.'s operating cash flow is $-47.8M, with capital expenditures of $414.0K. FCF margin is -6,032.3%.
How does IMA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -5,668.6% (avg: 12%), ROE -34.1% (avg: 15%), current ratio 12.49 (avg: 2).